百济神州今日宣布RATIONALE-315研究的最终分析结果和RATIONALE-303研究的长期随访数据显示百泽安(替雷利珠单抗)在两项研究中均取得临床意义的总生存期(OS)获益具体数据在2025年世界肺癌大会(WCLC)分别以简短口头报告和壁报形式公布。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.